HRP20110433T1 - Nove terapijske upotrebe inekalcitola - Google Patents
Nove terapijske upotrebe inekalcitola Download PDFInfo
- Publication number
- HRP20110433T1 HRP20110433T1 HR20110433T HRP20110433T HRP20110433T1 HR P20110433 T1 HRP20110433 T1 HR P20110433T1 HR 20110433 T HR20110433 T HR 20110433T HR P20110433 T HRP20110433 T HR P20110433T HR P20110433 T1 HRP20110433 T1 HR P20110433T1
- Authority
- HR
- Croatia
- Prior art keywords
- intended
- inecalcitol
- accordance
- day
- agents
- Prior art date
Links
- BUDPDEVHCQIFNU-PUBYVPDWSA-N inecalcitol Chemical compound C1(/[C@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CC#CC(C)(C)O)C)=C/C=C1/C[C@@H](O)C[C@H](O)C1=C BUDPDEVHCQIFNU-PUBYVPDWSA-N 0.000 title claims abstract 18
- 229950003028 inecalcitol Drugs 0.000 title claims abstract 18
- 230000001225 therapeutic effect Effects 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 claims abstract 4
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims abstract 3
- 201000002980 Hyperparathyroidism Diseases 0.000 claims abstract 3
- 201000004681 Psoriasis Diseases 0.000 claims abstract 3
- 201000011510 cancer Diseases 0.000 claims abstract 3
- 201000006417 multiple sclerosis Diseases 0.000 claims abstract 3
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract 2
- 208000001132 Osteoporosis Diseases 0.000 claims abstract 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims abstract 2
- 229930003316 Vitamin D Natural products 0.000 claims abstract 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims abstract 2
- 201000010099 disease Diseases 0.000 claims abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 2
- 208000005368 osteomalacia Diseases 0.000 claims abstract 2
- 208000007442 rickets Diseases 0.000 claims abstract 2
- 235000019166 vitamin D Nutrition 0.000 claims abstract 2
- 239000011710 vitamin D Substances 0.000 claims abstract 2
- 150000003710 vitamin D derivatives Chemical class 0.000 claims abstract 2
- 229940046008 vitamin d Drugs 0.000 claims abstract 2
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 230000003262 anti-osteoporosis Effects 0.000 claims 1
- 230000001028 anti-proliverative effect Effects 0.000 claims 1
- 230000002682 anti-psoriatic effect Effects 0.000 claims 1
- 239000013059 antihormonal agent Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Transplantation (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Reproductive Health (AREA)
- Oncology (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17990609P | 2009-05-20 | 2009-05-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110433T1 true HRP20110433T1 (hr) | 2011-07-31 |
Family
ID=42308305
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110433T HRP20110433T1 (hr) | 2009-05-20 | 2011-06-09 | Nove terapijske upotrebe inekalcitola |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US8481514B2 (https=) |
| EP (1) | EP2263677B1 (https=) |
| JP (2) | JP2012527424A (https=) |
| KR (1) | KR101845320B1 (https=) |
| CN (1) | CN102448466A (https=) |
| AT (1) | ATE505194T1 (https=) |
| AU (1) | AU2010261967B2 (https=) |
| BR (1) | BRPI1009056A2 (https=) |
| CA (1) | CA2762458C (https=) |
| DE (1) | DE602010000019D1 (https=) |
| DK (1) | DK2263677T3 (https=) |
| ES (1) | ES2363070T3 (https=) |
| HR (1) | HRP20110433T1 (https=) |
| IL (1) | IL216418A (https=) |
| MX (1) | MX2011012330A (https=) |
| NZ (1) | NZ596497A (https=) |
| PL (1) | PL2263677T3 (https=) |
| PT (1) | PT2263677E (https=) |
| RU (1) | RU2571490C2 (https=) |
| SG (1) | SG176581A1 (https=) |
| SI (1) | SI2263677T1 (https=) |
| UA (1) | UA105792C2 (https=) |
| WO (1) | WO2010145903A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE550318T1 (de) | 2010-01-26 | 2012-04-15 | Hybrigenics Sa | Neues verfahren zur isomerisierung kondensierter bicyclischer strukturen und herstellung von diese enthaltenden vitamin d analoga |
| US20120015913A1 (en) * | 2010-07-15 | 2012-01-19 | Delansorne Remi | Formulations of 14-EPI-Analogues of Vitamin D |
| EP2407152A1 (en) * | 2010-07-15 | 2012-01-18 | Hybrigenics S.A. | Formulations of 14-epi-analogues of vitamin D |
| EP2407155B1 (en) * | 2010-07-15 | 2012-12-26 | Hybrigenics S.A. | Formulations of inecalcitol |
| EP3157533A1 (en) * | 2014-06-19 | 2017-04-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Composition comprising a combination of dna methylation inhibitor and a vitamin d receptor agonist for the treatment of drug resistant cancer or for the prevention of tumor relapse |
| BR112018075206A2 (pt) | 2016-06-06 | 2019-03-19 | Celgene Corporation | tratamento de malignidade hematológica com 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida |
| JP2020143008A (ja) * | 2019-03-05 | 2020-09-10 | 達也 楠堂 | 新規褐色脂肪細胞分化誘導剤 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2153491C2 (ru) | 1993-07-09 | 2000-07-27 | Лаборатуар Терамекс С.А. | Аналоги витамина d, соединения, способы их получения и фармацевтическая композиция |
| US6242434B1 (en) * | 1997-08-08 | 2001-06-05 | Bone Care International, Inc. | 24-hydroxyvitamin D, analogs and uses thereof |
| GB0305332D0 (en) * | 2003-03-10 | 2003-04-09 | Leuven K U Res & Dev | Biological evaluation of novel vitamin D analogues |
| AU2005289664A1 (en) * | 2004-09-24 | 2006-04-06 | Bioxell S.P.A. | 20-cycloalkyl,26,27-alkyl/haloalkyl vitamin D3 compounds and methods of use thereof |
-
2010
- 2010-05-18 KR KR1020117030464A patent/KR101845320B1/ko not_active Expired - Fee Related
- 2010-05-18 PT PT10163156T patent/PT2263677E/pt unknown
- 2010-05-18 CA CA2762458A patent/CA2762458C/en not_active Expired - Fee Related
- 2010-05-18 RU RU2011151854/15A patent/RU2571490C2/ru not_active IP Right Cessation
- 2010-05-18 DE DE602010000019T patent/DE602010000019D1/de active Active
- 2010-05-18 PL PL10163156T patent/PL2263677T3/pl unknown
- 2010-05-18 AU AU2010261967A patent/AU2010261967B2/en not_active Ceased
- 2010-05-18 MX MX2011012330A patent/MX2011012330A/es active IP Right Grant
- 2010-05-18 AT AT10163156T patent/ATE505194T1/de active
- 2010-05-18 UA UAA201113630A patent/UA105792C2/uk unknown
- 2010-05-18 CN CN2010800222064A patent/CN102448466A/zh active Pending
- 2010-05-18 SI SI201030002T patent/SI2263677T1/sl unknown
- 2010-05-18 NZ NZ596497A patent/NZ596497A/xx not_active IP Right Cessation
- 2010-05-18 BR BRPI1009056-8A patent/BRPI1009056A2/pt not_active Application Discontinuation
- 2010-05-18 EP EP10163156A patent/EP2263677B1/en active Active
- 2010-05-18 WO PCT/EP2010/056832 patent/WO2010145903A1/en not_active Ceased
- 2010-05-18 SG SG2011085776A patent/SG176581A1/en unknown
- 2010-05-18 JP JP2012511265A patent/JP2012527424A/ja active Pending
- 2010-05-18 US US12/782,301 patent/US8481514B2/en not_active Expired - Fee Related
- 2010-05-18 DK DK10163156.2T patent/DK2263677T3/da active
- 2010-05-18 ES ES10163156T patent/ES2363070T3/es active Active
-
2011
- 2011-06-09 HR HR20110433T patent/HRP20110433T1/hr unknown
- 2011-11-17 IL IL216418A patent/IL216418A/en not_active IP Right Cessation
-
2016
- 2016-06-09 JP JP2016115489A patent/JP2016179994A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20110015276A1 (en) | 2011-01-20 |
| ES2363070T3 (es) | 2011-07-19 |
| KR20120017075A (ko) | 2012-02-27 |
| CN102448466A (zh) | 2012-05-09 |
| IL216418A0 (en) | 2012-02-29 |
| PL2263677T3 (pl) | 2011-09-30 |
| CA2762458C (en) | 2018-08-28 |
| RU2011151854A (ru) | 2013-06-27 |
| PT2263677E (pt) | 2011-06-01 |
| US8481514B2 (en) | 2013-07-09 |
| DE602010000019D1 (de) | 2011-05-26 |
| ATE505194T1 (de) | 2011-04-15 |
| IL216418A (en) | 2015-09-24 |
| DK2263677T3 (da) | 2011-06-06 |
| MX2011012330A (es) | 2011-12-16 |
| JP2016179994A (ja) | 2016-10-13 |
| NZ596497A (en) | 2013-05-31 |
| SG176581A1 (en) | 2012-01-30 |
| EP2263677A1 (en) | 2010-12-22 |
| UA105792C2 (uk) | 2014-06-25 |
| KR101845320B1 (ko) | 2018-04-04 |
| CA2762458A1 (en) | 2010-12-23 |
| RU2571490C2 (ru) | 2015-12-20 |
| SI2263677T1 (sl) | 2011-07-29 |
| AU2010261967B2 (en) | 2016-03-03 |
| WO2010145903A1 (en) | 2010-12-23 |
| EP2263677B1 (en) | 2011-04-13 |
| AU2010261967A1 (en) | 2011-12-08 |
| BRPI1009056A2 (pt) | 2020-06-02 |
| JP2012527424A (ja) | 2012-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110433T1 (hr) | Nove terapijske upotrebe inekalcitola | |
| Furtado et al. | Ursolic acid and oleanolic acid suppress preneoplastic lesions induced by 1, 2-dimethylhydrazine in rat colon | |
| MX2023001997A (es) | Compuestos biciclicos, composiciones y usos de los mismos. | |
| AR013878A1 (es) | Una composicion formulada para la aplicacion topica a tejidos, y el uso de dicha composicion para la manufactura de un medicamento para el tratamiento de psoriasis, artritis, para inhibir el rechazo de injertos, la estenosis y la recurrencia de tumor | |
| BR0006024A (pt) | Composição para o tratamento de inflamação e dor em mamìferos | |
| JP2012527424A5 (https=) | ||
| Khan et al. | Autophagy in adipogenesis: Molecular mechanisms and regulation by bioactive compounds | |
| JO2434B1 (en) | New retinoids to treat emphysema | |
| Kumano et al. | Dapsone in the treatment of miliary lupus of the face | |
| HRP20130237T1 (hr) | Formulacije inekalcitola | |
| AR023391A1 (es) | Composicion que contiene carnitina e inositol fosfato, util como suplemento dietario o droga | |
| PE20031047A1 (es) | Tratamiento de padecimientos post-menopausicos en pacientes con cancer de mama | |
| Nishioka | Drug, light, and oxygen: a dynamic combination in the clinic | |
| EP2275112A1 (en) | Antitumoral terpenoid pharmaceutical composition 'abisilin' exhibiting angiogenesis-inhibiting action | |
| Shaw et al. | The treatment of acne | |
| CN107072979B (zh) | 类黄酮化合物在制备伤口愈合组合物的用途 | |
| TN2022000289A1 (en) | Novel compound [2-(dimethylamino)-2-phenylbutyl]-3,4,5-trimethoxybenzoate 4-methyl-2н-chromen-2-on-7-yl sulphate and use thereof | |
| CL2004000631A1 (es) | Compuestos derivados del acido 6-(2-bromofenil)-pirido[2,3-dipirimidin-7-carboxilico; composicion farmaceutica; procedimiento de preparacion; y uso para tratar el cancer y para preparar medicamentos para inhibir el crecimiento tumoral. | |
| ES2031462T3 (es) | Procedimiento para producir 1-b-d-arabinofuranosilcitosina-5'-estearilfosfato monosodico y monohidrato de la misma, y compuesto farmaceutico que contiene esta ultima. | |
| US8188047B2 (en) | Therapeutic and cosmetic compositions for treatment of skin | |
| US20240216319A1 (en) | Tumor suppressant and pain relief composition for oral administration | |
| MXPA04011560A (es) | Formulacion anti-cancer. | |
| Lukovic et al. | Vanillin based chalcone analogue induces cell death in HeLa and HCT-116 cell line through mitochondrial apoptotic pathway | |
| RU2021118562A (ru) | Способ терапии и профилактики опухоли, поддающейся лечению эндокринной терапией, с помощью комбинированного применения ингибитора рецептора фактора роста фибробластов и эндокринной терапии | |
| Lizarelli et al. | Photobiomodulation for Pain Relief–A Comparative |